Kyle Doherty

Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.

Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.

The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.

[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.

The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.

Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.

Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

Nivolumab plus cabozantinib was safe and active for the real-world frontline treatment of patients with advanced RCC.

The FDA ODAC voted for the use of capivasertib plus abiraterone in PTEN-deficient mHSPC.

Capivasertib plus abiraterone produced superior efficacy outcomes vs abiraterone alone in PTEN-deficient mHSPC.

An NDA seeking the approval of varegacestat for the treatment of adult patients with desmoid tumors has been submitted to the FDA.

Alyssa Schatz, DrPH, discusses the new NCCN Advocacy Academy program for oncology fellows and junior faculty.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Fecal microbiota transplantation extended median PFS with first-line pembrolizumab plus axitinib in metastatic RCC.

Darlifarnib plus cabozantinib showed preliminary activity and safety across dose levels in cabozantinib-treated ccRCC.

With approximately 3 years of follow-up, TKI-naive patients with ROS1+ NSCLC experienced long-term benefits with taletrectinib.

The fourth-generation EGFR C797S inhibitor ABK-EGFR-1 showed promising in vivo efficacy in various EGFR C797S mutation models.

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

Joshua Lang, MD, MS, discusses the rationale for, and design of, the MEVPRO-1 and MEVPRO-2 studies in mCRPC.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.